Table 1.
Seroprevalence of HEV in blood donors
| Country | n | Seroprevalence, % | Method | Year [reference] |
|---|---|---|---|---|
| Japan | 12,600 | 3.4 | ELISA (in-house*, Cosmic corporation**) | 2010 [127] |
| Denmark | 461 | 20.6 | ELISA* (in-house) | 2008 [128] |
| Switzerland | 550 | 4.9 | ELISA* (MP Biomedicals) | 2011 [129] |
| The Netherlands | 1,275 | 0.4 | ELISA* (Abbott, Diagnostic Biotechnology), Westernblot** | 1993 [130] |
| Germany | 336 | 5.94 | Western blot (Mikrogen*), ELISA (MP Biomedicals**) | 2012 [28] |
| Germany | 1,019 | 6.8 | ELISA* (Mikrogen), Western blot** (Mikrogen) | 2013 [67] |
| Germany | 116 | 15.5 | Western blot* (Mikrogen) | 2011 [54] |
| England/Wales | 262 | 10.0 | ELISA* (Wantai), NAT*** (in-house) | 2011 [131] |
| Scotland | 1,559 | 4.7 | ELISA* (Wantai) | 2013 [59] |
| France | 1,998 | 3.2 | ELISA* (Genelabs Diagnostic) | 2007 [132] |
| France | 529 | 16.6 | ELISA* (Genelabs Diagnostics) | 2008 [66] |
| France | 512 | 52.2 | ELISA* (Wantai) | 2011 [65] |
*
Screening assay.
**
Supplemental assay for confirmation.
***
ELISA-positive samples were investigated by NAT.